All In Biotech

Drug Trial Radar · NCT04459325

Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

A Prospective Open-label Study of the Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

Last checked: Nov 20, 2026Latest source record: Oct 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Jun 1, 2020

Primary completion

Jul 20, 2020

Study completion Jul 20, 2020

Sponsor

Lead sponsor
AO GENERIUMIndustry
Sponsor type
Industry
First posted
Jul 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Tigerase® (GENERIUM JSC, Russia) with standard therapy versus standard therapy in patients with COVID-19.

Conditions

  • COVID-19
  • Coronavirus Disease 2019

Interventions

  • Tigerase® and best available careBiological

    Nebulised dornase alfa \[2.5 mg BID\] for 7 days

  • Best available careOther

    Patients will receive the usual care in accordance with good practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with mechanical ventilationTime frame: Day 8
  2. Category change on WHO Ordinal Scale for Clinical ImprovementTime frame: Day 8

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • City Clinical Hospital #15

    Moscow, Russia

  • I.M. Sechenov First Moscow State Medical University (Sechenov University)

    Moscow, Russia

  • City Clinical Hospital #51

    Moscow, Russia

  • City Clinical Hospital #52

    Moscow, Russia

  • N.V. Sklifosovsky Scientific Research Institute of First Aid

    Moscow, Russia

  • Siberian State Medical University (SibMed)

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.